Get the Stockscreener App
1.62
6.36%
-0.11
After Hours:
1.66
0.04
+2.47%
Macrogenics Inc stock is traded at $1.62, with a volume of 923.22K.
It is down -6.36% in the last 24 hours and up +8.72% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
See More
Previous Close:
$1.73
Open:
$1.75
24h Volume:
923.22K
Relative Volume:
1.02
Market Cap:
$102.39M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.0253
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
+1.89%
1M Performance:
+8.72%
6M Performance:
-25.69%
1Y Performance:
-52.21%
1-Day Range:
$1.60
$1.75
1-Week Range:
$1.46
$1.75
52-Week Range:
$0.9897
$5.10
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.62 | 109.35M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Resumed | Barclays | Overweight |
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
Acadian Asset Management LLC Buys 1,017,726 Shares of MacroGenics, Inc. $MGNX - MarketBeat
What indicators show strength in MacroGenics Inc.Weekly Investment Report & Free Growth Oriented Trading Recommendations - newser.com
Live market analysis of MacroGenics Inc.Earnings Recap Summary & High Conviction Buy Zone Alerts - newser.com
Using economic indicators to assess MacroGenics Inc. potential2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
MacroGenics (NASDAQ:MGNX) Rating Increased to Strong-Buy at Barclays - MarketBeat
MacroGenics Inc. stock trend outlook and recovery pathDay Trade & Daily Technical Stock Forecast Reports - newser.com
Growth Recap: Will MacroGenics Inc outperform the market in YEARJuly 2025 Sentiment & Fast Entry High Yield Tips - khodrobank.com
Macro Review: Why is Alpha Modus Holdings Inc Equity Warrant stock going upEarnings Trend Report & Smart Money Movement Tracker - khodrobank.com
MacroGenics Inc. recovery potential after sell off2025 Market Outlook & Low Drawdown Momentum Trade Ideas - newser.com
Quarterly Earnings: What is MacroGenics Inc.’s market positionJuly 2025 Movers & Weekly High Conviction Trade Ideas - khodrobank.com
Insider Buy: What makes MacroGenics Inc stock attractive todayTrade Entry Summary & Reliable Price Breakout Signals - khodrobank.com
Intraday pattern recognizer results for MacroGenics Inc.July 2025 PostEarnings & Real-Time Volume Analysis - newser.com
Barclays Begins Coverage on MacroGenics (NASDAQ:MGNX) - MarketBeat
MGNX Stock: Barclays Assumes Overweight Rating with $3 Price Tar - GuruFocus
How sentiment analysis helps forecast MacroGenics Inc.IPO Watch & Entry Point Strategy Guides - newser.com
MacroGenics, Inc. (NASDAQ:MGNX) Receives $3.60 Consensus Price Target from Brokerages - MarketBeat
Visualizing MacroGenics Inc. stock with heatmapsEarnings Risk Report & Fast Gain Swing Alerts - newser.com
Volatility clustering patterns for MacroGenics Inc.July 2025 Levels & Stepwise Entry and Exit Trade Signals - newser.com
MacroGenics assumed with an Overweight at Barclays - TipRanks
Buy Signal: What is the next catalyst for MacroGenics IncBuy Signal & Weekly High Potential Stock Alerts - خودرو بانک
Macro Review: Is HCSG stock a falling knife or bargain buyPortfolio Update Report & Expert Verified Stock Movement Alerts - khodrobank.com
Fed Watch: Is reAlpha Tech Corp. a turnaround storyJuly 2025 Setups & Advanced Technical Analysis Signals - خودرو بانک
Statistical indicators supporting MacroGenics Inc.’s strengthTrade Performance Summary & Weekly High Potential Alerts - newser.com
Downgrade Watch: What is MacroGenics Inc. s 5 year growth outlook2025 Growth vs Value & Trade Opportunity Analysis - خودرو بانک
Hedge Fund Bets: Can MacroGenics Inc. grow without dilutionMarket Risk Analysis & Reliable Price Breakout Alerts - خودرو بانک
Investment Report: Can LFUS lead its sector in growthMarket Growth Report & High Accuracy Investment Signals - خودرو بانک
Stock Analysis: Can MacroGenics Inc. reach all time highs this yearChart Signals & Precise Swing Trade Entry Alerts - خودرو بانک
Sentiment Review: What makes MacroGenics Inc stock attractive todayTrade Entry Report & Long-Term Safe Investment Ideas - khodrobank.com
Fund Flows: Can MacroGenics Inc be the next market leaderJuly 2025 Drop Watch & Accurate Buy Signal Notifications - khodrobank.com
Take Profit: Is MacroGenics Inc. stock forming a triangle patternJuly 2025 PostEarnings & Entry Point Strategy Guides - khodrobank.com
Analyst Calls: What is MacroGenics Inc. s 5 year growth outlook2025 Sector Review & Verified Momentum Stock Alerts - khodrobank.com
Multi asset correlation models including MacroGenics Inc.Quarterly Trade Review & Technical Pattern Based Buy Signals - newser.com
Nuveen LLC Purchases Shares of 198,470 MacroGenics, Inc. $MGNX - MarketBeat
Stifel Maintains Macrogenics(MGNX.US) With Hold Rating, Cuts Target Price to $4 - 富途牛牛
MacroGenics at H.C. Wainwright Conference: Strategic Antibody Advances By Investing.com - Investing.com South Africa
MacroGenics at H.C. Wainwright Conference: Strategic Antibody Advances - Investing.com India
Published on: 2025-09-08 14:52:02 - beatles.ru
MacroGenics Inc. Flashes Buy Signal on Multi Timeframe ChartJuly 2025 Earnings & Fast Entry Momentum Alerts - beatles.ru
Long term hold vs stop loss in MacroGenics Inc.Buy Signal & Accurate Buy Signal Notifications - Newser
Can MacroGenics Inc. reach all time highs this yearPortfolio Growth Summary & Technical Analysis for Trade Confirmation - خودرو بانک
What is MacroGenics Inc.’s market position2025 Growth vs Value & Short-Term Trading Alerts - خودرو بانک
What is the next catalyst for MacroGenics Inc.Portfolio Performance Summary & Real-Time Stock Price Movement Reports - خودرو بانک
Top chart patterns to watch in MacroGenics Inc.Weekly Profit Summary & Reliable Intraday Trade Alerts - Newser
Can MacroGenics Inc. stock double in the next yearEarnings Beat & Real-Time Volume Analysis - خودرو بانک
Will MacroGenics Inc. benefit from macro trendsPortfolio Gains Summary & Stepwise Entry/Exit Trade Alerts - Newser
MacroGenics' Strategic Divestitures and Implications for Biotech Innovation - AInvest
MacroGenics: Struggling Wheeler- Dealer Dealt Away Its Best Bets (NASDAQ:MGNX) - Seeking Alpha
Can MacroGenics Inc. recover in the next quarterLayoff News & Smart Swing Trading Techniques - Newser
What to do if you’re stuck in MacroGenics Inc.Market Activity Recap & AI Optimized Trade Strategies - Newser
Smart tools for monitoring MacroGenics Inc.’s price actionJuly 2025 Patterns & Safe Entry Momentum Tips - Newser
Macrogenics, Inc. shares rise 2.58% premarket after Johnson & Johnson's Alzheimer research progress and AstraZeneca's successful drug trial. - AInvest
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):